1.Le Roith, D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997; 336, 633–640.
2.Monzavi, R, Cohen, P. IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab. 2002; 16, 443–447.
3.Rajaram, S, Baylink, DJ, Mohan, S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997; 18, 801–831.
4.Rother, KI, Accili, D. Role of insulin receptors and IGF receptors in growth and development. Pediatr Nephrol. 2000; 14, 558–561.
5.Delafontaine, P, Song, YH, Li, Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004; 24, 435–444.
6.Kim, H-S, Rosenfeld, RG, Oh, Y. Biological roles of insulin-like growth factor binding proteins (IGFBPs). Exp Mol Med. 1997; 29, 85–96.
7.Wolf, E, Lahm, H, Wu, M, Wanke, R, Hoeflich, A. Effects of IGFBP-2 overexpression in vitro and in vivo. Pediatr Nephrol. 2000; 14, 572–578.
8.Ahmad, I, Beharry, KDA, Valencia, AM, et al. Influence of a single course of antenatal betamethasone on the maternal-fetal insulin-IGF-GH axis in singleton pregnancies. Growth Horm IGF Res. 2006; 16, 267–275.
9.Gohlke, BC, Fahnenstich, H, Dame, C, Albers, N. Longitudinal data for intrauterine levels of fetal IGF-I and IGF-II. Horm Res. 2004; 61, 200–204.
10.Gohlke, BC, Huber, A, Hecher, K, et al. Fetal insulin-like growth factor (IGF)-I, IGF-II, and ghrelin in association with birth weight and postnatal growth in monozygotic twins with discordant growth. J Clin Endocrinol Metab. 2005; 90, 2270–2274.
11.Lassare, C, Hardouin, S, Daffos, F, et al. Serum insulin-like growth factor and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res. 1991; 29, 219–225.
12.Reece, EA, Wiznittzer, A, Le, E, et al. The relation between human fetal growth and fetal blood levels of insulin-like growth factors I and II, their binding proteins, and receptors. Obstet Gynecol. 1994; 84, 88–95.
13.Westwood, M. Role of insulin-like growth factor binding protein 1 in human pregnancy. Rev Reprod. 1999; 4, 160–167.
14.Le Roith, D, Werner, H, Beitner-Johnson, D, Roberts, CT. The IGF System: Molecular Biology, Physiology and Clinical Applications, 1999. Humana Press, Inc.: Totowa, NJ, USA.
15.Smith, GD, Gunnell, D, Holly, J. Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ. 2000; 321, 847–848.
16.Constancia, M, Hemberger, M, Hughes, J, et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature. 2002; 417, 945–948.
17.Robertson, EJ. Insulin-like growth factors, imprinting and embryonic growth control. Dev Biol. 1995; 6, 293–299.
18.Sara, VR, Hall, K. Insulin-like growth factors and their binding proteins. Physiol Rev. 1990; 70, 591–614.
19.Firth, SM, Baxter, RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23, 824–854.
20.Salih, DA, Tripathi, G, Holding, C, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci U S A. 2004; 101, 4314–4319.
21.Williams, LA, Evans, SF, Newnham, JP. Prospective cohort study of factors influencing the relative weights of the placenta and the newborn infant. BMJ. 1997; 314, 1864–1868.
22.Newnham, JP, Evans, SF, Michael, CA, Stanley, FJ, Landau, LI. Effects of frequent ultrasound during pregnancy: a randomised controlled trial. Lancet. 1993; 342, 887–891.
23.Jaddoe, V, Bakker, R, van Duijn, C. The Generation R Study Biobank: a resource for epidemiological studies in children and their parents. Eur J Epidemiol. 2007; 22, 917–923.
24.Jaddoe, VW, van Duijn, CM, van der Heijden, AJ, et al. The Generation R Study: design and cohort update 2010. Eur J Epidemiol. 2010; 25, 823–841.
25.Mook-Kanamori, DO, Marsh, JA, Warrington, NM, et al. Variants near CCNL1/LEKR1 and in ADCY5 and fetal growth characteristics in different trimesters. J Clin Endocrinol Metab. 2011; 96, E810–E815.
26.Carter, KW, McCaskie, PA, Palmer, LJ. SimHap GUI: an intuitive graphical user interface for genetic association analysis. BMC Bioinform. 2008; 9, 557.
27.Laird, NM, Ware, JH. Random-effects models for longitudinal data. Biometrics. 1982; 38, 963–974.
28.R: A Language and Environment for Statistical Computing [computer program], 2009, Vienna, Austria: R Foundation for Statistical Computing, URL http://www.R-project.org.
29.Gao, X, Starmer, J, Martin, ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008; 32, 361–369.
30.Massague, J, Czech, MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 1982; 257, 5038–5045.
31.Jones, IJ, Clemmons, DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995; 16, 3–34.
32.Rechler, MM. Insulin-like growth factor binding proteins. Vitam Horm. 1993; 47, 1–114.
33.Barker, DJ. The fetal origins of adult hypertension. J Hypertens Suppl. 1992; 10, S39–S44.
34.Barker, DJ. Intrauterine programming of coronary heart disease and stroke. Acta Paediatr Suppl. 1997; 423, 178–182; discussion 183.
35.Barker, DJ. The developmental origins of chronic adult disease. Acta Paediatr Suppl. 2004; 93, 26–33.
36.Barker, DJ. The developmental origins of insulin resistance. Horm Res. 2005; 64(Suppl. 3), 2–7.
37.Barker, DJ. The origins of the developmental origins theory. J Intern Med. 2007; 261, 412–417.
38.Barker, DJ, Osmond, C, Golding, J, Kuh, D, Wadsworth, ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989; 298, 564–567.
39.Newnham, JP, Pennell, CE, Lye, SJ, Rampono, J, Challis, JR. Early life origins of obesity. Obstet Gynecol Clin North Am. 2009; 36, 227–244, xii.
40.Abuzzahab, MJ, Schneider, A, Goddard, A, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003; 349, 2211–2222.
41.Callan, AC, Milne, E. Involvement of the IGF system in fetal growth and childhood cancer: an overview of potential mechanisms. Cancer Causes Control. 2009; 20, 1783–1798.
42.Frayling, TM, Hattersley, AT, McCarthy, A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes. 2002; 51, 2313–2316.
43.Mohan, S, Amarnani, S, Baylink, DJ. Insulin-like growth factors and their binding proteins: role in pre- and postnatal growth and development. Inland Pediatr. 1991; 6, 1–7.
44.Pirazzoli, P, Cacciari, E, De Iasio, R, et al. Developmental pattern of fetal growth hormone, insulin-like growth factor I, growth hormone binding protein and insulin-like growth factor binding protein-3. Arch Dis Child Fetal Neonatal Ed. 1997; 77, F100–F104.
45.Freathy, RM, Mook-Kanamori, DO, Sovio, U, et al. Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet. 2010; 42, 430–435.
46.Hattersley, AT, Tooke, JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet. 1999; 353, 1789–1792.
47.Weng, L, Macciardi, F, Subramanian, A, et al. SNP-based pathway enrichment analysis for genome-wide association studies. BMC Bioinform. 2011; 12, 99.
48.Peng, G, Luo, L, Siu, H, et al. Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet. 2010; 18, 111–117.
49.Tisi, DK, Liu, X, Wykes, LJ, Skinner, CD, Koskl, KG. Insulin-like growth factor II and binding proteins 1 and 3 from second trimester human amniotic fluid are associated with infant birth weight. J Nutr. 2005; 135, 1667–1672.
50.El-Shewy, HM, Luttrell, LM. Insulin-like growth factor-2/mannose-6 phosphate receptors. Vitam Horm. 2009; 80, 667–697.
51.Kalus, W, Zweckstetter, M, Renner, C, et al. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. 1998; 17, 6558–6572.
52.Neumann, GM, Marinaro, JA, Bach, LA. Identification of O-glycosylation sites and partial characterization of carbohydrate structure and disulfide linkages of human insulin-like growth factor binding protein 6. Biochemistry. 1998; 37, 6572–6585.
53.Carrick, FE, Forbes, BE, Wallace, JC. BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J Biol Chem. 2001; 276, 27120–27128.
54.Galanis, M, Firth, SM, Bond, J, et al. Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. J Endocrinol. 2001; 169, 123–133.
55.Siwanowicz, I, Popowicz, GM, Wisniewska, M, et al. Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure. 2005; 13, 155–167.
56.Forbes, BE, McCarthy, P, Norton, RS. Insulin-like growth factor binding proteins: a structural perspective. Front Endocrinol (Lausanne). 2012; 3, 1–13.
57.Busby, WH Jr, Klapper, DG, Clemmons, DR. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation of two forms with different biologic actions. J Biol Chem. 1988; 263, 14203–14210.
58.Yu, J, Iwashita, M, Kudo, Y, Takeda, Y. Phosphorylated insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1 stimulates IGF-I-induced amino acid uptake by cultured trophoblast cells. Growth Horm IGF Res. 1998; 8, 65–70.
59.Hoflich, A, Lahm, H, Blum, W, Kolb, H, Wolf, E. Insulin-like growth factor-binding proteins-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Lett. 1998; 434, 329–334.
60.Mohseni-Zadeh, S, Binoux, M. Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. Endocrinology. 1997; 138, 5645–5648.